论文部分内容阅读
目的探讨经尿道前列腺切除术(TUR-P)联合间歇性或持续性雄激素阻断治疗晚期前列腺癌的疗效。方法选取2007年1月至2010年5月间收治的62例晚期前列腺癌患者,按随机排列表法分为观察组和对照组,每组各31例。观察组采取TUR-P联合间歇性雄激素阻断治疗,对照组采取TUER-P联合持续性雄激素阻断治疗,比较两组患者术后3个月国际前列腺症状评分(IPSS)、生活质量评分(QOL)、残余尿量(RUV)、最大尿流率(Qmax)、3年生存率以及不良反应。结果观察组患者术后IPSS、QOL、3年总生存率分别为(7.01±1.62)分、(1.79±0.46)分和83.9%,对照组患者则分别为(7.92±1.11)分、(2.16±0.34)分和58.1%,观察组明显优于对照组,差异有统计学意义(P<0.05)。观察组患者术后RUV为(25.61±8.21)ml,Qmax为(16.13±2.98)ml/s;对照组患者术后RUV为(26.01±7.51)ml,Qmax为(15.93±3.22)ml/s。观察组患者潮热症、骨质疏松、腹泻不良反应发生率分别为19.35%、12.90%和3.23%,对照组患者分别为61.29%、35.48%和19.35%,两组差异有统计学意义(P<0.05)。结论 TUR-P联合间歇性雄激素阻断治疗晚期前列腺癌能够明显改善患者预后,减少不良反应,值得临床推广。
Objective To investigate the efficacy of transurethral resection of the prostate (TUR-P) combined with intermittent or continuous androgen blockade in the treatment of advanced prostate cancer. Methods Sixty - two patients with advanced prostate cancer who were admitted between January 2007 and May 2010 were divided into observation group and control group according to randomized table method, with 31 cases in each group. The observation group was treated with TUR-P and intermittent androgen blockade. The control group was treated with TUER-P combined with continuous androgen blockade. The scores of International Prostate Symptom Score (IPSS), Quality of Life Scale QOL, RUV, Qmax, 3-year survival and adverse reactions. Results The total postoperative IPSS, QOL, and 3-year overall survival were (7.01 ± 1.62) points and (1.79 ± 0.46) points and 83.9% in the observation group and 7.92 ± 1.11 and 2.16 ± 0.34) and 58.1%, the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). The RUV in the observation group was (25.61 ± 8.21) ml and the Qmax was (16.13 ± 2.98) ml / s in the observation group. The RUV in the control group was (26.01 ± 7.51) ml and the Qmax was (15.93 ± 3.22) ml / s. In the observation group, the rates of hot flashes, osteoporosis and diarrhea were 19.35%, 12.90% and 3.23%, respectively, and those in the control group were 61.29%, 35.48% and 19.35%, respectively <0.05). Conclusion Combined TUR-P and intermittent androgen blockade in the treatment of advanced prostate cancer can significantly improve the prognosis of patients and reduce adverse reactions, which is worthy of clinical promotion.